Inactive Instrument

Oncolix, Inc. Stock

Equities

ONCX

US68236C1062

Biotechnology & Medical Research

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Dynamic Chart
Oncolix Announces Board Resignations CI
Oncolix, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2018 CI
Oncolix, Inc. announced that it has received $0.083 million in funding from PowerUp Lending Group, Ltd. CI
Oncolix, Inc. Finalizes its License Agreement from IGL Pharma, Inc. for Novel, Clinical Stage Drug for the Treatment of Osteosarcoma CI
Oncolix, Inc. Appoints Robert Niecestro as Member of its Regulatory Strategy, Scientific and Clinical Advisory Board CI
Oncolix, Inc. Elects Sherry Grisewood as Director CI
Oncolix Seeks Acquisitions CI
Oncolix, Inc. announced that it has received $1.034699 million in funding from Mario Family Partners, Concordia Capital Partners, LLC, Northbridge Financial Services, Manchester Management Company, LLC, Pacific Capital Management, FirstFire Capital Management LLC CI
Oncolix, Inc. Auditor Raises 'Going Concern' Doubt CI
Oncolix Initiates Patient Recruitment of Second Cohort of Prolanta™ Phase 1 Trial in Advanced Ovarian Cancer CI
Oncolix, Inc Announces Appointment of John W. Holaday as Board of Directors CI
Advanced Environmental Petroleum Producers, Inc. will Change its Ticker to ONCX from AEPP CI
Oncolix, Inc. Reports Unaudited Earnings Results for the Three Months Ended March 31, 2017 CI
Oncolix, Inc Announces Appointment of Board of Directors CI
Oncolix, Inc. Auditor Raises 'Going Concern' Doubt CI
More news
Managers TitleAgeSince
Chief Executive Officer 69 -
Members of the board TitleAgeSince
Chief Executive Officer 69 -
More insiders
Oncolix, Inc., formerly Advanced Environmental Petroleum Producers Inc., is a clinical-stage biopharmaceutical company. The Company is primarily focused on the development of Prolanta, a biological drug for the treatment of cancer. The Company's initial focus is ovarian cancer, and commenced a Phase I clinical trial of Prolanta for the treatment of ovarian cancer. Prolanta is effective in the treatment of breast, uterine, prostate and other cancers. The Company's Prolanta is a genetically modified form of human prolactin, a hormone associated with various types of cancers. Prolanta is designed to bind to the prolactin receptor on cells to block the effects of human prolactin. Human prolactin has documented to cause cancer cell proliferation by interacting with cancer cells. The Company has conducted animal studies to determine the efficacy of Prolanta in treating breast and ovarian cancers.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW